Search
Now showing items 1-3 of 3
Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment.
(WILEY, 2023-04-01)
AIMS: We systematically studied the presence of hyperglycaemia during treatment with Immune Checkpoint Inhibitors (ICPI) for cancer, in those with and without diabetes at baseline, and determined the cause of new-onset ...
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
(AMER ASSOC CANCER RESEARCH, 2023-01-17)
PURPOSE: This was a Phase I/II trial of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737 given in combination with gemcitabine. Its objectives were to establish the safety profile, recommended Phase 2 dose (RP2D), ...
A tailored approach to horizon scanning for cancer medicines.
(ELSEVIER SCI LTD, 2023-12-01)
BACKGROUND: Horizon scanning (HS) is the systematic identification of emerging therapies to inform policy and decision-makers. We developed an agile and tailored HS methodology that combined multi-criteria decision analysis ...